News | News By Subject | News by Disease News By Date | Search News

Leukemia [Chronic lymphocytic leukemia (CLL)] News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Juno (JUNO) Halts CAR-T Trial for Second Time Following Additional Patient Deaths     11/28/2016
Cancer Drug Developed by Eliza Hall Institute, AbbVie (ABBV) and Genentech (RHHBY) “Melts Away Cancer”     9/7/2016
Good News for Gilead (GILD) as Zydelig Passes Safety Review Test Despite Trial Deaths     7/12/2016
Infinity Pharma (INFI) Cuts Jobs by 58% as AbbVie (ABBV) Terminates Duvelisib Collaboration Deal     6/30/2016
FDA Green Lights AbbVie (ABBV), Genentech (RHHBY)'s New Chronic Lymphocytic Leukemia Drug Venclexta     4/12/2016
FDA Scorns Eagle Pharma (EGRX)'s Seven Year Orphan Drug Exclusivity Request for Blood Cancer Drug BENDEKA     3/28/2016
AbbVie (ABBV) and Roche (RHHBY)'s Venetoclax Snags Breakthrough Tag from the FDA for Blood Cancer     1/20/2016
Genentech (RHHBY) Touts Hematology Data for Gazyva and Venetoclax in CLL     12/17/2015
AbbVie (ABBV) Reveals Positive CLL Data at American Society of Hematology     12/7/2015
Genentech (RHHBY), AbbVie (ABBV) Confirm Venetoclax Met Primary Endpoint in Phase II Study     8/13/2015
AbbVie (ABBV), Genentech (RHHBY) Leukemia Drug Wins Breakthrough Status Tag     5/11/2015
AbbVie (ABBV) Elated as Pharmacyclics (PCYC)'s Imbruvica Shines in Combo Trial     3/20/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
EXCLUSIVE: AbbVie (ABBV) VP Says New Cancer Drug Could Treat Other Diseases     12/11/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014

News from Around the Web
Rituximab and Fludarabine Produce Long-Term Remissions in Some Chronic Lymphocytic Leukemia Patients, Ohio State University Study Suggests     3/1/2011
Rituximab Ups Survival in Chronic Lymphocytic Leukemia (CLL), University of Cologne Study     10/1/2010
Stem Cell Transplantation Successfully Treats Therapy-Resistant Chronic Leukemia, Heidelberg University Hospital Study Finds     7/13/2010
Complete Response with Oblimersen Combination Improves Survival of CLL Patients, M. D. Anderson Cancer Center Study     12/10/2007
Weizmann Institute of Science Scientists Discover: A Survival Mechanism for Blood Cancer Cells     8/28/2007
'Modular' Leukemia Drug Shows Promise in Early Testing, Ohio State University Study     6/29/2007
New Lymphocytic Leukemia Treatment Found     2/16/2007
Pair Of MicroRNA Molecules Controls Major Oncogene In Most Common Leukemia     12/15/2006
The Day In Review: Genasense Gets Negative FDA Report     9/5/2006
Mouse Mimics Chronic Leukemia, Will Aid Drug Development     8/23/2006
Gene Profile Predicts Leukemia's Course     10/27/2005

Press Releases
Eagle Pharma (EGRX) And Teva (TEVA) Release: Centers for Medicare & Medicaid Services Establishes Unique J-Code For BENDEKA (Bendamustine Hydrochloride) Injection     11/2/2016
EMA Committee Conditionally Approves AbbVie (ABBV)'s Leukaemia Drug VENCLYXTO     10/14/2016
KaloBios (KBIO) Announces First Patient Dosed In Phase I Study Of Lenzilumab For The Treatment Of Chronic Myelomonocytic Leukemia     7/25/2016
Pfizer (PFE) Announces Final Results From Inotuzumab Ozogamicin Pivotal Phase III Study In Adults With Relapsed/Refractory Acute Lymphoblastic Leukemia     6/13/2016
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting     6/6/2016
ASCO2016: AbbVie (ABBV) Builds Upon Robust Body Of IMBRUVICA (Ibrutinib) Data With Phase 3 Longer-Term Studies In Patients With Chronic Lymphocytic Leukemia And Small Lymphocytic Lymphoma Presented At The American Society Of Clinical Oncology (ASCO) Annual Meeting     6/6/2016
Escend Pharmaceuticals, Inc. Receives Orphan Drug Designation From The FDA For ES-3000 Its Lead Compound In The Treatment Of Chronic Myeloid Leukemia (CML)     6/3/2016
AbbVie (ABBV) Release: European Commission (EC) Approves IMBRUVICA (Ibrutinib) For First-Line Treatment Of Patients With Chronic Lymphocytic Leukemia     5/31/2016
Janssen R&D To Present Data From Six Compounds Including Daratumumab And Ibrutinib At The 2016 ASCO Annual Meeting     5/19/2016
Xencor To Present At Upcoming Investor Conferences     5/17/2016
AbbVie (ABBV) Release: U.S. FDA Expands IMBRUVICA (Ibrutinib) Label To Include Overall Survival Data In Previously Untreated Chronic Lymphocytic Leukemia (CLL) And New Indication For Small Lymphocytic Lymphoma (SLL) Patients     5/9/2016
Janssen Biotech Inc. (JNJ) Release: FDA Expands IMBRUVICA Label To Include New Data From Two Key Phase 3 Trials, Adding Overall Survival And Combination Data     5/9/2016
Infinity Pharmaceuticals Inc. (INFI) Provides Company Update And Reports First Quarter 2016 Financial Results     5/5/2016
AbbVie (ABBV) Release: European Medicines Agency Issues Positive Opinion For The Use Of IMBRUVICA (Ibrutinib) As A First-Line Treatment For Chronic Lymphocytic Leukemia Patients     4/29/2016
Celgene (CELG) Reports First Quarter 2016 Operating And Financial Results     4/28/2016

//-->